Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studi...

Full description

Bibliographic Details
Main Authors: Mahesh Kudrimoti, Amarinthia Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Zack Scott, Jenna Elder, Stephen T. Sonis, Richard Straube, Oreola Donini
Format: Article
Language:English
Published: Elsevier 2017-09-01
Series:Biotechnology Reports
Subjects:
Innate
Immune
Oral mucositis
Head and neck cancer
Cancer supportive care
Dusquetide
Online Access:http://www.sciencedirect.com/science/article/pii/S2215017X17300693

Internet

http://www.sciencedirect.com/science/article/pii/S2215017X17300693

Similar Items